EBV LMP2-Specific TCRs for Faster and Safer T Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EBV-related diseases, such as nasopharyngeal carcinoma and lymphoma, are challenging due to low specificity and durability of existing T cell therapies, requiring multiple high-dose infusions and long preparation times, with potential off-target effects and side effects.
Innovation Solution
Development of T cell antigen receptors (TCRs) specifically targeting EBV latent membrane protein LMP2 peptides (FLYALALLL, SSCSSCPLSK, TYGPVFMSL/TYGPVFMCL) to trigger high cytokine production and enhance tumor cell killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cells are cultured in vitro to treat EBV-related diseases, then T cells can be prepared for therapy, but the preparation period is long resulting in relatively long waiting time for treatment
Solution Approach 1:
The patent identifies and characterizes T cell receptors (TCRs) that specifically recognize EBV LMP2 antigen-MHC complexes in advance. These pre-identified TCR sequences can be rapidly introduced into patient T cells through gene transduction, eliminating the need for long-term in vitro culture to select effective T cells. This preliminary identification of target-specific TCRs significantly reduces the preparation time while maintaining therapeutic efficacy.
2Reliability
If high-dose T cell infusions are administered to improve therapeutic effect, then tumor cell killing ability is enhanced, but off-target effects and side effects increase
Solution Approach 1:
The patent develops TCRs with highly specific binding characteristics for EBV LMP2 antigen-MHC complexes. The TCR variable regions are engineered to recognize specific epitopes (such as FLYALALLL for HLA-A*0201, PYLFWLAAI for HLA-A*2402) with high affinity and specificity. This localized specificity at the molecular recognition level ensures that T cells only attack target cells expressing the specific EBV LMP2 antigen-MHC complex, minimizing off-target effects even at high doses.
3Reliability
If multiple T cell infusions are required to achieve therapeutic effect, then tumor cell killing ability is improved, but treatment complexity and duration increase
Solution Approach 1:
The patent optimizes the affinity parameters of TCRs for EBV LMP2 antigen-MHC complexes by selecting and engineering variable regions with specific amino acid sequences. The TCRs are designed to bind with high affinity (low Kd values) to target complexes, enabling effective tumor cell killing at lower T cell doses. This parameter optimization reduces the number of infusions needed while maintaining therapeutic efficacy.
4Measurement precision
If T cells are cultured for extended periods to increase specificity, then antigen recognition ability is improved, but T cell differentiation changes resulting in weak in vivo functions
Solution Approach 1:
The patent pre-identifies and characterizes TCR sequences with optimal specificity for EBV LMP2 antigen-MHC complexes before introducing them into patient T cells. The TCR variable regions are selected and engineered to recognize specific epitopes with high specificity. This preliminary optimization ensures that T cells maintain both high antigen recognition specificity and strong in vivo functional capacity without requiring extended culture periods that would cause differentiation changes.
Data Source
AI summary
Provided is an antibody or an antigen-binding fragment thereof, a T cell antigen receptor, an immune cell expressing the T cell antigen receptor (TCR), and a preparation method therefor and the use thereof. The TCR can specifically recognize corresponding pMHC complexes, activate TCR T cells, and produce high-level cytokines IFNγ, IL2, TNFα, significantly kill target cells and prolong the life of tumor-bearing mice.